results
Last reviewed 01/2018
Considering the primary endpoint, exercise tolerance at 12 weeks, omapatrilat and lisinopril are equivalent:
- 24 sec increase in the omapatrilat group
- 31 sec increase in the lisinopril group (p=0.45)
There was a significant effect on the secondary endpoint of death, admission or discontinuation of treatment due to worsening heart failure:
- hazard ratio 0.52 (p=0.035)